Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Genedata Screener Adopted for all Plate-based Screening by Major Pharmas

Published: Sunday, January 20, 2013
Last Updated: Saturday, January 19, 2013
Bookmark and Share
More than half of the top 25 pharmaceutical companies now use Genedata Screener® to support plate-based screening, including High Content, Label-free, and Ion Channel Screening

Genedata, a leading provider of advanced software solutions for drug discovery and life science research, has announced that more than half of the world's top 25 pharmaceutical companies have adopted  Genedata Screener as their plate-based screening analysis platform. Also used by biotechnology companies, contract research organizations, and academic research institutions, Genedata Screener captures, analyzes, and manages all types of screening data on one platform. The system, which reduces data processing times by upwards to 80%, integrates with any plate-based instrument to support High, Medium and Low Throughput Screening, High Content Screening (HCS), Ion Channel Screening, Label-free (including thermal shift), and other assay technologies.
One Platform for All Plate-based Screening
The cost savings, productivity gains, and time efficiencies of a single-platform screening analysis system with built-in business logic for standardized and automated workflows are driving the accelerated adoption of Genedata Screener. Addressing the complete screening workflow, Genedata Screener scales from the smallest datasets with single read-outs per well to 1,000s of plates in 1536-well format with full kinetics resolution. Its intuitive data analysis environment enables very fast experiment set-up, data import and processing with set-up times reduced by more than 50% compared to other systems. Genedata Screener uniquely supports the complete range of:

Classic Plate-based Screening Instruments
Fluorescence Polarization, FRET  
High Content Screening
Numeric well and cell results stored in files or databases
Images from local or central image storage
Off-the shelf support for
Molecular Devices MDC Store™ Data Management
openBIS for HCS
Perkin Elmer Columbus™ Image Data Management
Thermo Scientific Cellomics® Store  
Time Series results as produced in
FLIPR-/FDSS-based Screening
Ion Channel Screening
Label-free Screening
Thermal Shift Screening
Industry Adoption - Co-Development Drives Innovation
The system's data analysis capabilities are further advanced through co-development projects with leading pharmaceutical companies. Currently, the Genedata  team is working with customers to have Genedata Screener support native processing for calculation of compound combination effects - such as synergy or antagonistic effects. Exploring compound combination effects is a rapidly expanding field in pharmaceutical and biotechnology research. Genedata Screener provides a standardized platform on which researchers can systematically, reliably and efficiently visualize and explore the scientific principles of compound combinations is critical to furthering innovation in drug and treatment discovery.
"Over the past two years, we have seen Genedata Screener's adoption more than double, making it the de-facto screening analysis standard at leading pharmaceutical companies," said Dr. Othmar Pfannes, CEO of Genedata. "The increased use of Genedata Screener is also due in part to our commitment to industry collaborations that drive innovative research. For example, our collaborations will develop the industry's first commercial platform to fully support quantification of drug combination effect as part of a complete interactive and multi-dimensional screening workflow."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Genedata Signs License Agreement with AstraZeneca
Genedata Screener now AstraZeneca’s corporate platform for expediting drug discovery.
Saturday, November 21, 2015
Kymab Implements Genedata Biologics for High-throughput Antibody Discovery
Genedata Biologics™ integrated workflow platform used to increase throughput and automation of Kymab’s transgenic mice-based discovery platforms.
Tuesday, November 17, 2015
Genedata Completes Important Milestone in Collaboration with Bayer Pharma AG
Successful integration of Genedata Profiler™ allows researchers to access, process, analyze and manage petabytes of NGS and other omics data from patients and pre-clinical experiments.
Thursday, September 24, 2015
Merck Serono Chooses Genedata Biologics to Streamline Antibody Discovery Processes
Global deployment of Genedata Biologics across multiple protein therapeutics R&D groups to standardize workflows and improve efficiency.
Thursday, July 23, 2015
Genedata Releases a Breakthrough for Genomic Comparison
Genedata Selector™4.0 provides reference-independent genome sequence comparisons while reducing data processing and analysis time to optimize efficiency and save costs.
Wednesday, July 22, 2015
Genedata Forges Alliance with Intellicyt
Swiss informatics firm Genedata and Intellicyt today announced an alliance to work on cell-based screening in drug discovery.
Thursday, June 18, 2015
Precision Medicine Software Genedata Profiler™ Launched at Bio-IT World
Open, interoperable enterprise platform for patient and compound profiling provides important data management infrastructure for pharma internal R&D processes.
Friday, April 24, 2015
Partner on Innovative Workflow Platform for High-Throughput Cell Line Development
Novel Cell Line Development (CLD) data platform to support the generation and assessment of mammalian production cell lines.
Tuesday, March 17, 2015
Genedata, Bayer Pharma AG Partner on Innovative Workflow Platform for High-Throughput Cell Line Development
Novel Cell Line Development (CLD) data platform to support the generation and assessment of mammalian production cell lines.
Tuesday, March 17, 2015
Genedata Biologics Licensed by Pfizer
Pfizer implements Genedata Biologics to streamline global biopharma R&D processes.
Wednesday, March 04, 2015
Boehringer Ingelheim Selects Genedata Biologics as Antibody Discovery Workflow Platform
Genedata Biologics integrates and streamlines workflows for protein therapeutics R&D groups across multiple Boehringer Ingelheim sites.
Thursday, February 19, 2015
Genedata Highlights Combination Screening and Surface Plasmon Resonance at SLAS 2015
Colloquium and tutorials on Combination Screening and SPR examine Genedata Screener as the platform for all plate-based screening experiments.
Wednesday, February 04, 2015
Takara Bio Selects Genedata Software to Automate and Standardize NGS Data Analysis
Genedata Expressionist® for Genomic Profiling helps Takara Bio to manage, process, and analyze large NGS datasets.
Wednesday, November 05, 2014
Exploring Innovations in SPR & Combination Screening
Genedata customers will discuss innovations in high content imaging, high throughput screening, compound combination screening, and other related topics at User Group Meetings.
Tuesday, August 26, 2014
GSK Implements Genedata Biologics as Antibody Discovery Platform
Genedata Biologics integrates GlaxoSmithKline's Biopharm Discovery workflows across multiple Biopharm R&D groups and sites
Thursday, June 12, 2014
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Promising Drug Combination for Advanced Prostate Cancer
A new drug combination may be effective in treating men with metastatic prostate cancer. Preliminary results of this new approach are encouraging and have led to an ongoing international study being conducted in 196 hospitals worldwide.
A Cellular Symphony Responsible for Autoimmune Disease
Broad Institute researchers have used a novel approach to increase our understanding of the immune system as a whole.
When it Comes to Breast Cancer, Common Pigeon is No Bird Brain
If pigeons went to medical school and specialized in pathology or radiology, they’d be pretty good at distinguishing digitized microscope slides and mammograms of normal vs. cancerous breast tissue, a new study has found.
Editing of LIMS Data Made Faster and More Efficient in Matrix Gemini
The latest version of the Matrix Gemini LIMS (Laboratory Information Management System) from Autoscribe Informatics now provides faster and more efficient editing of LIMS data by eliminating the need for a second editing screen.
University of Edinburgh, Selcia Achieve Key Milestones in Drug Development Program
Scientists from the University of Edinburgh, working with Selcia, have successfully passed the 20-month milestone targets of a 30-month Wellcome Trust SDDi £2.5 million project to design novel treatments for sleeping sickness.
Red Clover Genome to Help Restore Sustainable Farming
The Genome Analysis Centre (TGAC) in collaboration with IBERS, has sequenced and assembled the DNA of red clover to help breeders improve the beneficial traits of this important forage crop.
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Tech Vastly Improves CRISPR/Cas9 Accuracy
A new CRISPR/Cas9 technology developed by scientists at UMass Medical School is precise enough to surgically edit DNA at nearly any genomic location, while avoiding potentially harmful off-target changes typically seen in standard CRISPR gene editing techniques.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos